Israel Englander Corvus Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 181,200 shares of CRVS stock, worth $713,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares

181,200

Previous 152,800 18.59%

Holding current value

$713,928

Previous $806,000 16.87%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$4.55 - $9.56 $711,560 - $1.5 Million	-156,387 Reduced 50.24%	154,901 $805,000
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $189,908 - $631,604	106,690 Added 52.15%	311,288 $1.64 Million
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $246,591 - $415,215	181,317 Added 778.82%	204,598 $372,000
Q1 2024 May 15, 2024	SELL	$1.76 - $2.41 $30,895 - $42,305	-17,554 Reduced 42.99%	23,281 $41,000
Q4 2023 Feb 14, 2024	BUY	$1.08 - $1.92 $44,101 - $78,403	40,835 New	40,835 $71,000
Q1 2023 May 15, 2023	BUY	$0.65 - $0.92 $84,439 - $119,514	129,907 Added 6.84%	2,029,423 $1.85 Million
Q4 2022 Feb 14, 2023	SELL	$0.74 - $1.04 $270,689 - $380,427	-365,796 Reduced 16.15%	1,899,516 $1.62 Million
Q3 2022 Nov 14, 2022	SELL	$0.71 - $1.17 $300,068 - $494,478	-422,631 Reduced 15.72%	2,265,312 $1.85 Million
Q2 2022 Aug 15, 2022	SELL	$0.87 - $2.03 $30,968 - $72,259	-35,596 Reduced 1.31%	2,687,943 $2.66 Million
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $286,919 - $487,369	-196,520 Reduced 6.73%	2,723,539 $4.47 Million
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $5.46 Million - $12.4 Million	2,331,787 Added 396.38%	2,920,059 $7.04 Million
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $863,421 - $3.9 Million	456,837 Added 347.58%	588,272 $2.85 Million
Q2 2021 Aug 16, 2021	BUY	$2.46 - $3.14 $79,553 - $101,544	32,339 Added 32.63%	131,435 $351,000
Q1 2021 May 17, 2021	SELL	$2.86 - $4.77 $64,412 - $107,429	-22,522 Reduced 18.52%	99,096 $305,000
Q4 2020 Feb 16, 2021	SELL	$3.56 - $4.86 $923,909 - $1.26 Million	-259,525 Reduced 68.09%	121,618 $433,000
Q3 2020 Nov 16, 2020	SELL	$2.6 - $5.37 $2.11 Million - $4.36 Million	-811,599 Reduced 68.04%	381,143 $1.53 Million
Q2 2020 Aug 14, 2020	BUY	$2.01 - $4.05 $323,575 - $651,981	160,983 Added 15.6%	1,192,742 $3.24 Million
Q1 2020 May 14, 2020	BUY	$1.74 - $5.98 $403,556 - $1.39 Million	231,929 Added 29.0%	1,031,759 $2.18 Million
Q4 2019 Feb 14, 2020	SELL	$2.56 - $5.44 $390,059 - $828,876	-152,367 Reduced 16.0%	799,830 $4.35 Million
Q3 2019 Nov 14, 2019	BUY	$3.01 - $6.5 $2.64 Million - $5.7 Million	877,462 Added 1174.1%	952,197 $2.87 Million
Q2 2019 Aug 14, 2019	BUY	$3.3 - $4.58 $184,486 - $256,044	55,905 Added 296.89%	74,735 $280,000
Q1 2019 May 14, 2019	SELL	$3.75 - $4.97 $155,317 - $205,847	-41,418 Reduced 68.75%	18,830 $76,000
Q4 2018 Feb 14, 2019	BUY	$3.29 - $8.94 $75,268 - $204,529	22,878 Added 61.22%	60,248 $221,000
Q3 2018 Nov 14, 2018	SELL	$8.58 - $11.4 $2.64 Million - $3.51 Million	-308,204 Reduced 89.19%	37,370 $321,000
Q2 2018 Aug 14, 2018	SELL	$9.42 - $13.73 $2.45 Million - $3.57 Million	-259,729 Reduced 42.91%	345,574 $3.79 Million
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $4.09 Million - $6.3 Million	546,286 Added 925.64%	605,303 $6.98 Million
Q4 2017 Feb 14, 2018	BUY	$9.3 - $16.93 $353,381 - $643,306	37,998 Added 180.78%	59,017 $611,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $237,514 - $362,157	21,019	21,019 $335,000

Others Institutions Holding CRVS

# of Institutions

102

Shares Held

38.1M

Call Options Held

2.75M

Put Options Held

1.17M

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $183M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account